Multidrug-resistant tuberculosis (MDR-TB) is one of the most serious public health problems in the world today—and the global burden is growing. That’s why we are delighted to announce that UNITAID has awarded Partners In Health a grant that will change how MDR-TB is treated throughout the world.
Partnering with Médecins Sans Frontières and Interactive Research & Development, PIH will use the four-year, $60 million grant to bring two new drugs to 17 countries in which MDR-TB poses a significant burden. Called “END-TB,” this project is designed to dramatically expand access to these new drugs globally. It will lead to the development of new treatment regimens for MDR-TB and ultimately improve the quality of life for countless patients.
Here’s everything you need to know about this innovative program.
Source: Partners In Health